Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT314 + Pumitamig + Chemotherapy in Metastatic Colorectal Cancer
NCT07079631Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Jul 2025
- Primary completion
- Dec 2030
- Modality
- Bispecific Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of GEN1059 in metastatic colorectal cancer (mCRC), sponsored by BioNTech SE. Started Jul 2025; status: recruiting.
02
Drugs
GEN1059
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07079631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07079631.